{"id":"NCT01235442","sponsor":"Amgen","briefTitle":"Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","officialTitle":"A Randomized Study to Evaluate the Efficacy and Safety of Adding Topical Therapy to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2011-10","completion":"2011-12","firstPosted":"2010-11-05","resultsPosted":"2013-10-31","lastUpdate":"2018-08-07"},"enrollment":592,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"1=Etanercept","otherNames":[]},{"type":"DRUG","name":"2=Clobetasol propionate foam","otherNames":[]}],"arms":[{"label":"etanercept and clobetasol","type":"EXPERIMENTAL"},{"label":"etanercept","type":"EXPERIMENTAL"}],"summary":"The primary hypothesis of this trial is that the addition of short courses of clobetasol propionate foam to etanercept monotherapy in subjects with moderate to severe plaque psoriasis will yield greater efficacy compared with etanercept monotherapy, as measured by PASI 75 at Week 12.","primaryOutcome":{"measure":"PASI 75 at Week 12","timeFrame":"Week 12","effectByArm":[{"arm":"Etanercept Monotherapy","deltaMin":48.3,"sd":null},{"arm":"Etanercept + Clobetasol Propionate Foam","deltaMin":65.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23643256"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":301},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Sinusitis"]}}